Search clinical trials for: Linagliptin Pioglitazone

Total 1198 results

Boehringer Ingelheim
Eli Lilly and Company

Completed

30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks

Diabetes Mellitus, Type 2

United States, Estonia, Germany, Latvia, Spain, United Kingdom
Daiichi Sankyo Co., Ltd.

Completed

Placebo and Active Comparator Controlled Dose Response Study of Rivoglitazone in Type 2 Diabetes (RAISE)

Type 2 Diabetes

China
Boehringer Ingelheim

Completed

Relative Bioavailability of Two Fixed Dose Combination Tablets of Linagliptin/Pioglitazone Compared With Single Linagliptin and Pioglitazone Tablets Administered Together to Healthy Male and Female Subjects

Healthy
Boehringer Ingelheim

Completed

Bioequivalence of a Fixed Dose Combination Tablet Linagliptin/Pioglitazone Compared With Its Mono-components

Healthy

Germany
Emory University
Merck Sharp & Dohme LLC

Terminated

DPP-4 Inhibition and TZD for DM Prevention (DInT DM)

Prediabetic State

United States
Boehringer Ingelheim

Completed

Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM

Diabetes Mellitus, Type 2

United States, Argentina, Austria, Belgium, Canada, China, Croatia, Czech Republic, Finland, Germany, Greece, Hungary, India, Israel, Italy, Japan, Korea, Republic of, Malaysia, Mexico, Netherlands, New Zealand, Philippines, Poland, R... and more
Daiichi Sankyo, Inc.

Terminated

Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
Boehringer Ingelheim

Completed

Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone

Diabetes Mellitus, Type 2

Austria, Greece, Hungary, Japan, Portugal, Romania, Spain
Merck Sharp & Dohme LLC

Completed

Sitagliptin and Pioglitazone Mechanism of Action Study in Type 2 Diabetes Mellitus (0431-061)

Type 2 Diabetes Mellitus (T2DM)
Daiichi Sankyo, Inc.

Completed

Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes

Type 2 Diabetes

United States
Merck Sharp & Dohme LLC

Completed

MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)

Type 2 Diabetes Mellitus
Boehringer Ingelheim

Completed

The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients

Diabetes Mellitus, Type 2

Germany
Merck Sharp & Dohme LLC

Completed

Initial Combination With Pioglitazone Study (0431-064)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)

Type 2 Diabetes Mellitus
Daiichi Sankyo, Inc.

Completed

Study of Rivoglitazone in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States, Germany, Mexico, Romania, Serbia, South Africa, Ukraine, Chile, Peru, Puerto Rico, Austria, Hungary, Slovakia, India, Czechia, Latvia, Argentina, United Kingdom
Merck Sharp & Dohme LLC

Completed

MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (MK0431-023)

Diabetes Mellitus, Type 2
Metabolic Solutions Development Company

Completed

Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients

Type 2 Diabetes

United States
Sung-Chen Liu
Mackay Memorial Hospital

Completed

Adding Sitagliptin or Pioglitazone to Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin and Sulfonylurea (JAS)

Type 2 Diabetes

Taiwan
Merck Sharp & Dohme LLC

Completed

MK0431 (Sitagliptin) Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus (0431-055)(COMPLETED)

Type 2 Diabetes Mellitus
Dong-A ST Co., Ltd.

Completed

Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5 mg and Pioglitazone 30 mg

Type 2 Diabetes

Korea, Republic of
Tehran University of Medical Sciences

Completed

Sitagliptin vs. Pioglitazone as add-on Treatments in Patients With Type 2 Diabetes Uncontrolled on the Full-dose Metformin Plus Sulfonylurea

Uncontrolled Type 2 Diabetes Mellitus

Iran, Islamic Republic of
Sun Yat-sen University

Unknown

Effects of Different Early Intensive Therapies on Long-term β-cell Function

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Completed

Sulfonylurea Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-035)

Diabetes Mellitus, Type 2
Solvay Pharmaceuticals

Completed

A Methodological Study To Evaluate The Effects of Single Oral Doses Of Pioglitazone 45 mg And Rosiglitazone 8 mg On Sodium Balance In Healthy Male Volunteers

Type 2 Diabetes Mellitus

United Kingdom
Brigham and Women's Hospital
Patient-Centered Outcomes Research Institute; McGill University; VA Boston Healthcare...

Active, not recruiting

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study (CER-4-T2D)

Type2 Diabetes | Renal Disease | Cardiovascular Events

United States
Merck Sharp & Dohme LLC

Completed

Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2
AstraZeneca
Eli Lilly and Company

Completed

Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)

Type 2 Diabetes Mellitus

United States, Brazil, Italy, Korea, Republic of, Mexico, Poland, Russian Federation, Spain, Turkey, United Kingdom, South Africa, Argentina, Canada, Germany, Hungary, Israel, Romania, Slovakia, India, Belgium, France, Puerto Rico
University of Campinas, Brazil

Active, not recruiting

Study of Imatinib Discontinuation in Chronic Myeloid Leukemia With Deep Molecular Response (EDI-PIO)

Leukemia, Chronic Myeloid

Brazil
Boehringer Ingelheim

Completed

Bioavailability of BI 1356 With and Without Co-administration of Pioglitazone and the Bioavailability of Pioglitazone With and Without Coadministration of BI 1356 in Healthy Male and Female Volunteers

Healthy
Azienda Ospedaliero-Universitaria di Parma

Active, not recruiting

Managing DIabetes Remission After Combined Therapy in EarLy Stage of DiabetEs (MIRACLE)

Newly Diagnosed Type 2 Diabetes

Italy
Royal Devon and Exeter NHS Foundation Trust
King's College London; Newcastle University; NHS Tayside; University of Dundee; University... and other collaborators

Completed

TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes. (TriMaster)

Type 2 Diabetes

United Kingdom
AstraZeneca
Eli Lilly and Company

Completed

A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)

Type 2 Diabetes Mellitus

United States, Mexico, India
JW Pharmaceutical

Completed

MAGE of Anagliptin Compared With Sitagliptin With Type 2 Diabetes Mellitus (ACACIA)

Type 2 Diabetes

Korea, Republic of
University at Buffalo
Takeda Pharmaceuticals North America, Inc.

Completed

Effect of Pioglitazone on Oxidative Load, Inflammatory End-Points and Vascular Reactivity in Obese Non-Diabetic Patients: A Dose Ranging Study

Inflammation

United States
Emory University

Completed

Ketosis Prone Diabetes in African-Americans

Diabetic Ketoacidosis | Ketosis Prone Diabetes | Severe Hyperglycemia

United States
Assistance Publique - Hôpitaux de Paris
Ministry of Health, France

Not yet recruiting

A Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RENATO Trial (RENATO)

ANCA Associated Vasculitis | Rapidly Progressive Glomerulonephritis | Crescentic Glomerulonephritis
National Cancer Institute (NCI)

Completed

Pioglitazone Hydrochloride in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia

Head and Neck Cancer | Oral Leukoplakia

United States
University of Campinas, Brazil

Recruiting

The Role of Pioglitazone in Vascular Transcriptional Remodeling (PREVALENT)

Myocardial Reperfusion Injury

Brazil
West Virginia University

Recruiting

Pioglitazone Therapy Targeting Fatigue in Breast Cancer

Breast Cancer | Muscle Fatigue

United States
University of Texas Southwestern Medical Center
National Institutes of Health (NIH)

Completed

Pioglitazone on Pancreatic Steatosis and Bone Health

Obesity | Type 2 Diabetes

United States
Centre Hospitalier Universitaire Dijon

Completed

Influence of Glitazones on the Vasodilatory Effect of High-density Lipoprotein (HDL) Lipoproteins

Type 2 Diabetes

France
Merck Sharp & Dohme LLC

Completed

Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)

Diabetes Mellitus, Type II
University of Texas Southwestern Medical Center

Recruiting

Pathogenesis of Uric Acid Nephrolithiasis: Role of Pioglitazone/Weight Loss

Nephrolithiasis, Uric Acid

United States
Technische Universität Dresden

Completed

Influence of Pioglitazone for Renal Transplant Function in Diabetics

Diabetes Mellitus | Proteinuria | Kidney Transplantation

Germany
GlaxoSmithKline

Completed

Study In Patients With Type 2 Diabetes Who Are Taking Metformin And Sulfonylurea, Metformin And Insulin, Or Insulin

Non-Insulin-Dependent Diabetes Mellitus

United States
Medical University of South Carolina
Takeda Pharmaceuticals North America, Inc.

Completed

Pioglitazone and Serum Asymmetric Dimethylarginine (ADMA) in Patients With Diabetes

Diabetes

United States
National Cancer Institute (NCI)

Terminated

Pioglitazone for Oral Premalignant Lesions

Oral Leukoplakia

United States, Italy, Canada

3

Subscribe